PT1212061E - Composicoes injectaveis de microparticulas de buprenorfina e suas utilizacoes - Google Patents
Composicoes injectaveis de microparticulas de buprenorfina e suas utilizacoesInfo
- Publication number
- PT1212061E PT1212061E PT00959422T PT00959422T PT1212061E PT 1212061 E PT1212061 E PT 1212061E PT 00959422 T PT00959422 T PT 00959422T PT 00959422 T PT00959422 T PT 00959422T PT 1212061 E PT1212061 E PT 1212061E
- Authority
- PT
- Portugal
- Prior art keywords
- methadone
- partial
- opioid antagonist
- opioid agonist
- buprenorfine
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical group C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 2
- 229960001736 buprenorphine Drugs 0.000 title abstract 2
- 239000007972 injectable composition Substances 0.000 title 1
- 239000011859 microparticle Substances 0.000 title 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 abstract 4
- 229960001797 methadone Drugs 0.000 abstract 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000003402 opiate agonist Substances 0.000 abstract 3
- 239000003401 opiate antagonist Substances 0.000 abstract 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 abstract 1
- 229960002069 diamorphine Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 1
- 229960003086 naltrexone Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15111299P | 1999-08-27 | 1999-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1212061E true PT1212061E (pt) | 2005-01-31 |
Family
ID=22537367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT00959422T PT1212061E (pt) | 1999-08-27 | 2000-08-25 | Composicoes injectaveis de microparticulas de buprenorfina e suas utilizacoes |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6495155B1 (pt) |
| EP (1) | EP1212061B1 (pt) |
| JP (1) | JP4913298B2 (pt) |
| KR (1) | KR100730440B1 (pt) |
| CN (2) | CN100387228C (pt) |
| AT (1) | ATE280579T1 (pt) |
| AU (1) | AU765496C (pt) |
| BR (1) | BR0013650A (pt) |
| CA (1) | CA2382577C (pt) |
| CY (1) | CY1106043T1 (pt) |
| CZ (1) | CZ2002728A3 (pt) |
| DE (1) | DE60015370T2 (pt) |
| EA (1) | EA009080B1 (pt) |
| ES (1) | ES2230154T3 (pt) |
| HK (1) | HK1046858B (pt) |
| HU (1) | HUP0203613A3 (pt) |
| IL (2) | IL148343A0 (pt) |
| MX (1) | MXPA02002105A (pt) |
| NO (2) | NO322650B1 (pt) |
| NZ (1) | NZ517997A (pt) |
| PL (1) | PL198334B1 (pt) |
| PT (1) | PT1212061E (pt) |
| RO (1) | RO121631B1 (pt) |
| WO (1) | WO2001015699A1 (pt) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148343A0 (en) * | 1999-08-27 | 2002-09-12 | Southern Res Inst | Injectable buprenorphine microparticle compositions and their use |
| US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| ES2385030T3 (es) * | 2001-06-29 | 2012-07-17 | Medgraft Microtech, Inc. | Implantes inyectables biodegradables y procedimientos relacionados con su fabricación y uso |
| AU2002303148A1 (en) * | 2001-06-29 | 2003-03-03 | Leon J. Lewandowski | Individualized addiction cessation therapy |
| WO2003004030A1 (en) | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oxymorphone controlled release formulations |
| US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| BR0205722A (pt) * | 2001-07-06 | 2005-04-05 | Penwest Pharmaceuticals Compan | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor |
| AU2002337686B2 (en) * | 2001-09-26 | 2008-05-15 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US7131997B2 (en) | 2002-03-29 | 2006-11-07 | Scimed Life Systems, Inc. | Tissue treatment |
| US7094369B2 (en) | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
| US7053134B2 (en) | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
| SI2561860T1 (en) | 2002-05-31 | 2018-05-31 | Titan Pharmaceuticals, Inc. | An implantable polymeric device for prolonged release of buprenorphine |
| US7041320B1 (en) * | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
| US7842377B2 (en) * | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US7449236B2 (en) | 2002-08-09 | 2008-11-11 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
| US7588825B2 (en) | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
| WO2004078178A1 (en) * | 2003-03-03 | 2004-09-16 | Markus Heilig | Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use |
| US20050031667A1 (en) | 2003-03-31 | 2005-02-10 | Patel Rajesh A. | Implantable polymeric device for sustained release of dopamine agonist |
| US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
| US7901770B2 (en) | 2003-11-04 | 2011-03-08 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
| US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
| US7919499B2 (en) | 2004-04-22 | 2011-04-05 | Alkermes, Inc. | Naltrexone long acting formulations and methods of use |
| FR2869801B1 (fr) * | 2004-05-05 | 2008-09-12 | Ethypharm Sa | Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc) |
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| NZ582130A (en) | 2004-08-04 | 2011-11-25 | Clinuvel Pharmaceuticals Ltd | Methods of inducing melanogenesis in a subject |
| US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
| US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
| US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| US20070141160A1 (en) * | 2005-12-15 | 2007-06-21 | Brown Laura J | Method of treatment for osteoarthritis by local intra-articular injection of microparticles |
| US7501179B2 (en) | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| WO2008106571A2 (en) * | 2007-02-28 | 2008-09-04 | Abbott Laboratories | Sustained release parenteral formulations of buprenorphine |
| CA2699172C (en) * | 2007-09-03 | 2016-05-17 | Nanotherapeutics, Inc | Compositions and methods for delivery of poorly soluble drugs |
| JP5502751B2 (ja) * | 2007-12-20 | 2014-05-28 | エボニック コーポレイション | 低残留溶媒濃度を有する微粒子を調製するためのプロセス |
| CN104984343B (zh) * | 2008-09-24 | 2019-04-02 | 赢创罗姆有限公司 | 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物 |
| BRPI0823096B8 (pt) | 2008-09-24 | 2022-07-05 | Evonik Roehm Gmbh | composição farmacêutica de opióide de liberação controlada, dependente do ph, com resistência contra a influência do etanol, processo para sua preparação, e seu uso |
| KR101535701B1 (ko) | 2008-09-24 | 2015-07-09 | 에보니크 룀 게엠베하 | 에탄올의 영향에 대하여 내성을 갖는 비-오피오이드용 ｐｈ-의존성 조절 방출 제약 조성물 |
| US20100268191A1 (en) * | 2009-04-21 | 2010-10-21 | Medtronic Vascular, Inc. | Drug Delivery Catheter using Frangible Microcapsules and Delivery Method |
| US9125867B2 (en) | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| WO2013126552A1 (en) | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| JP6279547B2 (ja) | 2012-04-17 | 2018-02-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
| CN102836131A (zh) * | 2012-09-28 | 2012-12-26 | 山东大学 | 丁丙诺啡皮下注射用缓释微球制剂及其制备方法 |
| US9636308B2 (en) | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| US9393211B2 (en) * | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| JP6135292B2 (ja) * | 2013-05-10 | 2017-05-31 | ニプロ株式会社 | マイクロカプセル製剤の製造方法 |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| WO2016071767A1 (en) | 2014-11-07 | 2016-05-12 | Indivior Uk Limited | Buprenorphine dosing regimens |
| CN109069416A (zh) | 2016-02-23 | 2018-12-21 | 拜欧帝力威瑞科学有限公司 | 缓释丁丙诺啡微球(srbm)及其使用方法 |
| CA3033046C (en) | 2016-09-13 | 2021-09-07 | Alar Pharmaceuticals Inc. | Sustained-release buprenorphine formulations |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| AR117426A1 (es) | 2018-05-11 | 2021-08-04 | Alar Pharmaceuticals Inc | Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina |
| US20220313686A1 (en) * | 2019-08-12 | 2022-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pharmaceutical compositions comprising a combination of opioid antagonists |
| US20210059943A1 (en) * | 2019-09-04 | 2021-03-04 | Buffalo Pacific LLC | Systems and methods addressing multiple aspects to provide a comprehensive recovery program for addictions, chronic conditions and diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4568559A (en) | 1984-02-06 | 1986-02-04 | Biotek, Inc. | Composite core coated microparticles and process of preparing same |
| US4623588A (en) | 1984-02-06 | 1986-11-18 | Biotek, Inc. | Controlled release composite core coated microparticles |
| GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US5143661A (en) * | 1987-05-26 | 1992-09-01 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules |
| FR2618674B1 (fr) | 1987-07-30 | 1990-06-15 | Ire Celltarg Sa | Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation |
| GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| US4902515A (en) * | 1988-04-28 | 1990-02-20 | E. I. Dupont De Nemours And Company | Polylactide compositions |
| US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| ATE133087T1 (de) | 1989-05-04 | 1996-02-15 | Southern Res Inst | Einkapselungsverfahren |
| US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| AU2605592A (en) * | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US5633000A (en) | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
| US5716631A (en) | 1995-09-29 | 1998-02-10 | Rdn Therapeutics Inc. | Long acting narcotic analgesics and antagonists |
| US5919473A (en) * | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
| IL148343A0 (en) * | 1999-08-27 | 2002-09-12 | Southern Res Inst | Injectable buprenorphine microparticle compositions and their use |
-
2000
- 2000-08-25 IL IL14834300A patent/IL148343A0/xx active IP Right Grant
- 2000-08-25 AT AT00959422T patent/ATE280579T1/de not_active IP Right Cessation
- 2000-08-25 BR BR0013650-6A patent/BR0013650A/pt not_active Application Discontinuation
- 2000-08-25 CZ CZ2002728A patent/CZ2002728A3/cs unknown
- 2000-08-25 PL PL354977A patent/PL198334B1/pl not_active IP Right Cessation
- 2000-08-25 ES ES00959422T patent/ES2230154T3/es not_active Expired - Lifetime
- 2000-08-25 AU AU70751/00A patent/AU765496C/en not_active Ceased
- 2000-08-25 CA CA002382577A patent/CA2382577C/en not_active Expired - Lifetime
- 2000-08-25 EA EA200200295A patent/EA009080B1/ru not_active IP Right Cessation
- 2000-08-25 RO ROA200200190A patent/RO121631B1/ro unknown
- 2000-08-25 WO PCT/US2000/023390 patent/WO2001015699A1/en not_active Ceased
- 2000-08-25 JP JP2001519913A patent/JP4913298B2/ja not_active Expired - Lifetime
- 2000-08-25 KR KR1020027002567A patent/KR100730440B1/ko not_active Expired - Fee Related
- 2000-08-25 MX MXPA02002105A patent/MXPA02002105A/es active IP Right Grant
- 2000-08-25 US US09/648,255 patent/US6495155B1/en not_active Expired - Lifetime
- 2000-08-25 DE DE60015370T patent/DE60015370T2/de not_active Expired - Lifetime
- 2000-08-25 PT PT00959422T patent/PT1212061E/pt unknown
- 2000-08-25 EP EP20000959422 patent/EP1212061B1/en not_active Expired - Lifetime
- 2000-08-25 CN CNB2005100927174A patent/CN100387228C/zh not_active Expired - Fee Related
- 2000-08-25 CN CNB008147280A patent/CN1248689C/zh not_active Expired - Fee Related
- 2000-08-25 HU HU0203613A patent/HUP0203613A3/hu unknown
- 2000-08-25 HK HK02108436.3A patent/HK1046858B/en not_active IP Right Cessation
- 2000-08-25 NZ NZ517997A patent/NZ517997A/xx unknown
-
2002
- 2002-02-24 IL IL148343A patent/IL148343A/en not_active IP Right Cessation
- 2002-02-26 NO NO20020924A patent/NO322650B1/no not_active IP Right Cessation
- 2002-12-17 US US10/324,062 patent/US7473431B2/en not_active Expired - Lifetime
-
2005
- 2005-01-14 CY CY20051100081T patent/CY1106043T1/el unknown
-
2006
- 2006-07-12 NO NO20063239A patent/NO20063239L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1212061E (pt) | Composicoes injectaveis de microparticulas de buprenorfina e suas utilizacoes | |
| PL350548A1 (en) | Compositions of naltrexone microspheres for injection and their application in getting out of the habit of heroin and alcohol abuse | |
| DE60234183D1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
| WO2004091593A3 (en) | Methods for the treatment of pain comprising opioid antagonists | |
| ATE244558T1 (de) | Trockene formbare arzneistoffformulierung | |
| WO1999011250A3 (en) | Noribogaine in the treatment of pain and drug addiction | |
| WO2004060405A8 (en) | Tissue reactive compounds and compositions and uses thereof | |
| DE60013630D1 (de) | Arzneimittel zur behandlung von darmverstopfung und reizkolon | |
| Endoh et al. | TRK-820, a selective κ-opioid agonist, produces potent antinociception in cynomolgus monkeys | |
| Suzuki et al. | Involvement of δ1 and δ2 opioid receptor subtypes in the development of physical dependence on morphine in mice | |
| Przesmycki et al. | Isobolographic analysis of interaction between intrathecal morphine and clonidine in the formalin test in rats | |
| EP1555023A3 (en) | Injectable buprenorphine microparticle compositions and their use | |
| ATE287265T1 (de) | Verwendung von schwachen opioiden und gemischten opioidagonisten / -antagonisten zur therapie der harninkontinenz | |
| WO2002013759A3 (en) | Method of treating the syndrome of type 2 diabetes in humans | |
| Rudo et al. | Antinociceptive activity of pentamorphone, a 14-β-aminomorphinone derivative, compared to fentanyl and morphine | |
| PE20020041A1 (es) | Combinacion farmaceutica que comprende un compuesto de efecto opioide y un compuesto peptidico | |
| OELTGEN | Characterization and utilization of opiate-like hibernation factors(Report, 15 Jul. 1992- 15 Dec. 1993) | |
| Campi et al. | ZT 52656A: EEG spectral analysis in freely-moving rats | |
| Funada et al. | A new opioid analgesic KT90: Analgesia and dependence liability | |
| AUPS010302A0 (en) | Subcutaneous implant or injection combining opiate agonists and antagonists |